Global Immunotherapy Drugs Market

1 INTRODUCTION OF GLOBAL IMMUNOTHERAPY DRUGSMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL IMMUNOTHERAPY DRUGSMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA:
5.1 Overview
5.2 Cancer
5.3 Autoimmune and Inflammatory Diseases
5.4 Infectious Diseases
5.5 Other Therapy Areas

6 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER:
6.1 Overview
6.2 Hospitals
6.3 Clinics
6.4 Other End Users

7 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUG:
7.1 Overview
7.2 Monoclonal Antibodies
7.3 Adult Vaccines
7.3.1 Preventive Vaccines
7.3.2 Therapeutic Vaccines
7.4 Checkpoint Inhibitors
7.5 Interferons Alpha & Beta
7.6 Interleukins
7.7 Other Drugs

8 GLOBAL IMMUNOTHERAPY DRUGSMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

9 GLOBAL IMMUNOTHERAPY DRUGSMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 F. Hoffmann-La Roche AG
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Merck & Co., Inc.
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Novartis International AG
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.)
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Glaxosmithkline PLC
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Amgen Inc.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Abbvie
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Astrazeneca
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Bristol-Myers Squibb
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Development

10.10 ELI Lilly and Company
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Development

11 Appendix
11.1 Related Reports